Lamellipodin (D8A2K) Rabbit mAb #91138
- WB
- IF
Supporting Data
REACTIVITY | H |
SENSITIVITY | Endogenous |
MW (kDa) | 195 |
Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Immunofluorescence (Immunocytochemistry) | 1:200 |
Storage
Protocol
Specificity / Sensitivity
Lamellipodin (D8A2K) Rabbit mAb recognizes endogenous levels of total lamellipodin protein. Based on the amino acid sequence of the immunogenic peptide, this antibody is expected to detect the canonical isoform (RMO1-RAPH1) only.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro990 of human lamellipodin protein.
Background
Regulation of actin dynamics at the leading edge of the cell drives cell adhesion, migration, and invasion. These processes are crucial for normal development, immune cell function, angiogenesis and cell division, and are dysregulated in diseases such as metastatic cancer (1, 2).
Lamellipodin (Lpd) is a member of the Mig-10/RIAM/lamellipodin (MRL) family of adaptor proteins. Lamellipodin regulates the formation of lamellipodia at the leading edge through its interaction with and recruitment of actin-modulating proteins such as Ena/VASP (3) and the Scar/WAVE complex (4). Lamellipodin and Mena cooperate with endophilin to regulate EGFR endocytosis (5). MRL proteins can also form complexes with talin and activated integrins, guiding the formation of cell protrusions and the direction of cell migration (6).
- Rottner, K. and Stradal, T.E. (2011) Curr Opin Cell Biol 23, 569-78.
- Wells, A. et al. (2013) Trends Pharmacol Sci 34, 283-9.
- Hansen, S.D. and Mullins, R.D. (2015) Elife 4, .
- Law, A.L. et al. (2013) J Cell Biol 203, 673-89.
- Vehlow, A. et al. (2013) EMBO J 32, 2722-34.
- Lagarrigue, F. et al. (2015) Nat Commun 6, 8492.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.